ACHIEVE LIFE SCIENCES, INC. (ACHV) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, ACHIEVE LIFE SCIENCES, INC.'s filing signal turned negative.

Achieve Life Sciences, Inc. is a late-stage clinical specialty pharmaceutical company focused on addressing the global nicotine dependence epidemic with its sole product candidate, cytisinicline. The company has submitted a New Drug Application (NDA) to the FDA for smoking cessation, with a target action date of June 20, 2026, and has also received Breakthrough Therapy designation for nicotine e-cigarette cessation. Cytisinicline, a naturally occurring alkaloid, acts as a partial agonist/antagonist at nicotinic acetylcholine receptors in the brain to reduce cravings and withdrawal symptoms. The company has established partnerships for manufacturing and is pursuing regulatory approvals in the United States and potentially other global markets. Achieve Life Sciences operates with a lean structure, with 28 employees as of December 31, 2025, and maintains offices in Bothell, Washington, and Vancouver, British Columbia.

The company has not generated any revenue from product sales to date and anticipates that any future revenue will be attributable to sales of cytisinicline, primarily in the United States and the EU.